

## BACKGROUND

For many infectious diseases, approved therapies are either absent or unsatisfactory, and healthcare providers may use existing drugs in novel ways for patients with difficult-to-treat infections.

CURE ID began as a collaboration between FDA and the National Center for Advancing Translational Sciences (NCATS), part of the National Institutes of Health (NIH). FDA and NIH are also collaborating with the World Health Organization (WHO), the Infectious Diseases Society of America (IDSA), the Critical Path Institute (C-Path), and other partners to assess the global utility of the CURE ID platform.

The platform is a web-based tool, which enables healthcare providers to share their real-world experiences treating patients with repurposed drugs – existing drugs being used in a new way – through a simple online case report form on their smartphone, computer, or mobile device.

CURE ID can capture the treatment outcomes when drugs are used for new diseases or aspects of those diseases, new populations, in new doses, or in new combinations. Through CURE ID's ability to obtain and organize this information received directly from healthcare providers, promising new therapeutic uses can be identified for formal study by institutions involved in drug development, and unhelpful or harmful uses can potentially be avoided. The systematic collection of real-world experience reported to CURE ID will help to enhance the understanding of how existing medical products are being repurposed for new uses; may facilitate clinical trials and drug development; and can serve as a resource for healthcare providers to share information where a disease lacks adequate approved treatment options.

Users can view cases shared by healthcare professionals and those extracted from the published literature individually and in aggregate. In addition, they can view discussions and clinical trials from clinicaltrials.gov. They can also stay up-to-date on the latest infectious disease news through journal articles, news articles, and events that are updated daily. CURE ID aims to be a network connecting major treatment centers, academics, private practitioners, government facilities and other healthcare providers worldwide into a global clinical care community.

## WHAT IS THE VALUE OF CURE ID?

The CURE ID platform will enable collection of real-world treatment experience directly from healthcare providers in a systematic, accurate, and detailed manner. Information from CURE ID can be used to inform ongoing and future clinical trials and potentially drug labeling.

For example, it could:

- Serve as a platform for healthcare providers to exchange their treatment experiences about challenging diseases.
- Spur clinical trial development by collecting better information regarding positive and negative health outcomes about existing products, which may help drug developers narrow potential drug candidates for study. Ultimately, this program could help enrich the armamentarium of drugs available for diseases that are difficult to treat.
- Serve as a resource for healthcare providers to share information where a disease lacks adequate approved treatment options.
- Allow for the rapid identification of promising treatment approaches in urgent situations, such as during outbreaks of emerging infectious threats and use this information to inform clinical trials.
- Enable collection of real-world treatment experience directly from healthcare providers in a systematic, accurate, and detailed manner. Information from CURE ID can be used to inform ongoing and future clinical trials and potentially drug labeling.

## CASES OF INTEREST



Have you had a patient with an infection that had no sufficient approved treatments?



Have you had a patient who has failed previous approved therapies?



Have you had a patient who was unable to tolerate available approved therapies?


## LEARN MORE

To get in contact with the CURE ID Team

Email: [caresupport@mail.nih.gov](mailto:caresupport@mail.nih.gov)

Visit us at <https://cure.ncats.io> or

Download the **CURE ID** mobile



## CURE DRUG REPURPOSING COLLABORATORY



The **CURE Drug Repurposing Collaboratory (CDRC)** is a public-private partnership initiated in June 2020 by the Critical Path Institute (C-Path) and the U.S. Food and Drug Administration (FDA) in partnership with the National Center for Advancing Translational Sciences (NCATS), part of the National Institutes of Health (NIH).

Convened by C-Path, the public-private partnership will promote and manage the platform, as well as its individual and organizational participants.

The CDRC focuses on capturing relevant real-world clinical outcome data through the CURE ID platform. The objective is to accelerate the identification and development of potentially effective drugs for patients with diseases that lack adequate approved treatment options with the goal of helping identify drug candidates for additional study and potentially drug labeling in the future.

## NEXT STEPS

The Collaboratory will seek to do the following:

- Develop a campaign for deployment of the application worldwide.
- Train local healthcare personnel to use the application.
- Identify appropriate audiences to utilize CURE ID. This may include professional societies, academics, universities, private practitioners, etc.
- Identify and encourage disease experts to serve as moderators and develop disease-specific communities.
- Maintain and update the newsfeed.
- Develop other features to encourage use. This may include offering continuing medical education credits and adding informative content to improve the user appeal, publication options, breaking news on infectious diseases, etc.
- Contribute data and guidelines to include in the application.
- Review incoming data and identify literature mining opportunities.
- Evaluate entries into the application and make sure that disease experts respond to discussion posts and comment on cases.
- Seek to better understand how data could be generated through the collecting healthcare providers' real-world experiences to inform future clinical trials of drugs for additional indications of public health importance and high unmet need.
- Work to coordinate and streamline drug development efforts and identify any potential barriers to seeking FDA approval for indications with a limited or non-existent financial interest.

## PARTNERS & COLLABORATORS



World Health Organization



AIDS Alliance of America



## C-Path Invites you to Get Involved with the CDRC:

- Join as an Institutional Partner
- Become a CURE ID Curator
  - Contribute your dataset to the
- CURE ID database
- Participate as a CURE ID Clinical Champion

## LEARN MORE

Visit the Consortium's Website: <https://c-path.org/programs/cdrc/>  
Email: [cdrc@c-path.org](mailto:cdrc@c-path.org)